SUPPLEMENTAL CONSOLIDATING FINANCIAL INFORMATION - Supplemental Consolidating Statement of Cash Flow Information (Detail) (USD $) | 6 Months Ended |
Jun. 30, 2014 | Jun. 30, 2013 |
Cash flows from operating activities: | ' | ' |
Net income (loss) | ($82,185,000) | ($1,870,000) |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity in income of subsidiaries | 0 | 0 |
Depreciation, depletion, and amortization | 40,538,000 | 29,823,000 |
Accretion of asset retirement obligation and receivable | 9,288,000 | 6,338,000 |
Non-cash tax benefits | -224,000 | 0 |
Amortization of intangible assets and liabilities, net | 310,000 | 326,000 |
Share-based compensation | 2,445,000 | 3,771,000 |
Gain on sales of assets | -5,000 | -308,000 |
Amortization of deferred financing costs | 1,209,000 | 1,856,000 |
Loss on sales of investment securities | ' | -28,000 |
Loss on extinguishment of debt | 12,635,000 | 64,000 |
Loss (gain) on sales of investment securities | 3,000 | -28,000 |
Derivative loss | 5,930,000 | 0 |
Loss on foreign exchange | 4,141,000 | 0 |
Income from equity affiliates | -799,000 | 0 |
Distributions from equity affiliates | 730,000 | 0 |
Changes in operating assets and liabilities: | ' | ' |
Receivables, net | -11,270,000 | 3,687,000 |
Inventories | 22,770,000 | -1,977,000 |
Excess of black lung benefit obligation over trust assets | 1,166,000 | -281,000 |
Deferred income tax | 3,854,000 | 0 |
Accounts payable and accrued expenses | 8,538,000 | 1,701,000 |
Deferred revenue | -8,424,000 | -6,214,000 |
Income tax payable | 528,000 | -56,000 |
Accrual for workers' compensation | -125,000 | -284,000 |
Asset retirement obligations | -3,362,000 | -5,424,000 |
Accrual for postretirement medical benefits | 1,409,000 | 4,094,000 |
Pension and SERP obligations | -332,000 | 1,517,000 |
Other assets and liabilities | 1,805,000 | -1,811,000 |
Distributions received from subsidiaries | 0 | 0 |
Net cash provided by operating activities | 10,573,000 | 34,924,000 |
Cash flows from investing activities: | ' | ' |
Additions to property, plant and equipment | -17,361,000 | -13,467,000 |
Change in restricted investments and bond collateral and reclamation deposits | -30,517,000 | -8,714,000 |
Cash payments related to Canadian acquisition | -322,637,000 | 0 |
Cash acquired in related to Canadian acquisition | 8,103,000 | 0 |
Net proceeds from sales of assets | 213,000 | 577,000 |
Proceeds from sale of investments | 246,000 | 6,807,000 |
Increase in loan and lease receivable | -1,120,000 | 0 |
Receipts from loan and lease receivable | 2,164,000 | 0 |
Receivable from customer for property and equipment purchases | 0 | -308,000 |
Other | -82,000 | 0 |
Net cash used in investing activities | -360,991,000 | -15,105,000 |
Cash flows from financing activities: | ' | ' |
Change in book overdrafts | 1,605,000 | 1,777,000 |
Borrowings from long-term debt | 454,219,000 | 0 |
Repayments of long-term debt | -97,538,000 | -16,070,000 |
Borrowings on revolving lines of credit | 10,000,000 | 6,000,000 |
Repayments on revolving lines of credit | -10,000,000 | -6,000,000 |
Debt issuance costs and other refinancing costs | -27,053,000 | -182,000 |
Dividends/distributions | -470,000 | -680,000 |
Exercise of stock options | 193,000 | 0 |
Transactions with Parent/affiliates | 0 | 0 |
Net cash provided by (used in) financing activities | 330,956,000 | -15,155,000 |
Effect of foreign exchange rates on cash | -1,038,000 | 0 |
Net increase (decrease) in cash and cash equivalents | -20,500,000 | 4,664,000 |
Cash and cash equivalents, beginning of period | 61,110,000 | 31,610,000 |
Cash and cash equivalents, end of period | 40,610,000 | 36,274,000 |
Parent/ Issuer | ' | ' |
Cash flows from operating activities: | ' | ' |
Net income (loss) | -82,185,000 | -1,870,000 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity in income of subsidiaries | 16,148,000 | -27,450,000 |
Depreciation, depletion, and amortization | 156,000 | 187,000 |
Accretion of asset retirement obligation and receivable | 0 | 0 |
Non-cash tax benefits | -224,000 | ' |
Amortization of intangible assets and liabilities, net | 0 | 0 |
Share-based compensation | 1,934,000 | 1,567,000 |
Gain on sales of assets | 0 | 0 |
Amortization of deferred financing costs | 494,000 | 1,541,000 |
Loss on sales of investment securities | ' | 0 |
Loss on extinguishment of debt | 62,000 | 64,000 |
Loss (gain) on sales of investment securities | 0 | ' |
Derivative loss | 0 | ' |
Loss on foreign exchange | 5,233,000 | ' |
Income from equity affiliates | 0 | ' |
Distributions from equity affiliates | 0 | ' |
Changes in operating assets and liabilities: | ' | ' |
Receivables, net | 943,000 | -227,000 |
Inventories | 0 | 0 |
Excess of black lung benefit obligation over trust assets | 1,166,000 | -280,000 |
Deferred income tax | 0 | ' |
Accounts payable and accrued expenses | 17,348,000 | -1,957,000 |
Deferred revenue | 0 | 0 |
Income tax payable | 0 | 0 |
Accrual for workers' compensation | -125,000 | -284,000 |
Asset retirement obligations | 0 | 0 |
Accrual for postretirement medical benefits | -885,000 | -40,000 |
Pension and SERP obligations | 166,000 | 695,000 |
Other assets and liabilities | -7,429,000 | -49,000 |
Distributions received from subsidiaries | 76,800,000 | 36,600,000 |
Net cash provided by operating activities | 29,602,000 | 8,497,000 |
Cash flows from investing activities: | ' | ' |
Additions to property, plant and equipment | 16,000 | -575,000 |
Change in restricted investments and bond collateral and reclamation deposits | -48,188,000 | -807,000 |
Cash payments related to Canadian acquisition | -282,788,000 | ' |
Cash acquired in related to Canadian acquisition | 0 | ' |
Net proceeds from sales of assets | 0 | 0 |
Proceeds from sale of investments | 0 | 0 |
Increase in loan and lease receivable | 0 | ' |
Receipts from loan and lease receivable | 0 | ' |
Receivable from customer for property and equipment purchases | 0 | 0 |
Other | 0 | ' |
Net cash used in investing activities | -330,960,000 | -1,382,000 |
Cash flows from financing activities: | ' | ' |
Change in book overdrafts | 0 | 0 |
Borrowings from long-term debt | 454,219,000 | ' |
Repayments of long-term debt | -1,015,000 | -500,000 |
Borrowings on revolving lines of credit | 0 | 0 |
Repayments on revolving lines of credit | 0 | 0 |
Debt issuance costs and other refinancing costs | -15,407,000 | -26,000 |
Dividends/distributions | -470,000 | -680,000 |
Exercise of stock options | 193,000 | ' |
Transactions with Parent/affiliates | -147,974,000 | -5,080,000 |
Net cash provided by (used in) financing activities | 289,546,000 | -6,286,000 |
Effect of foreign exchange rates on cash | 0 | ' |
Net increase (decrease) in cash and cash equivalents | -11,812,000 | 829,000 |
Cash and cash equivalents, beginning of period | 25,326,000 | 14,836,000 |
Cash and cash equivalents, end of period | 13,514,000 | 15,665,000 |
Co-Issuer | ' | ' |
Cash flows from operating activities: | ' | ' |
Net income (loss) | -7,842,000 | 3,829,000 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity in income of subsidiaries | 0 | 0 |
Depreciation, depletion, and amortization | 5,009,000 | 5,082,000 |
Accretion of asset retirement obligation and receivable | 34,000 | 32,000 |
Non-cash tax benefits | 0 | ' |
Amortization of intangible assets and liabilities, net | 290,000 | 312,000 |
Share-based compensation | 14,000 | 23,000 |
Gain on sales of assets | 0 | 0 |
Amortization of deferred financing costs | 0 | 0 |
Loss on sales of investment securities | ' | 0 |
Loss on extinguishment of debt | 0 | 0 |
Loss (gain) on sales of investment securities | 0 | ' |
Derivative loss | 5,930,000 | ' |
Loss on foreign exchange | 0 | ' |
Income from equity affiliates | 0 | ' |
Distributions from equity affiliates | 0 | ' |
Changes in operating assets and liabilities: | ' | ' |
Receivables, net | -6,000 | -1,995,000 |
Inventories | 842,000 | -1,632,000 |
Excess of black lung benefit obligation over trust assets | 0 | 0 |
Deferred income tax | 0 | ' |
Accounts payable and accrued expenses | -1,101,000 | 4,101,000 |
Deferred revenue | -4,791,000 | -4,190,000 |
Income tax payable | 0 | 0 |
Accrual for workers' compensation | 0 | 0 |
Asset retirement obligations | 0 | 0 |
Accrual for postretirement medical benefits | 0 | 0 |
Pension and SERP obligations | 2,000 | 9,000 |
Other assets and liabilities | -273,000 | 101,000 |
Distributions received from subsidiaries | 0 | 0 |
Net cash provided by operating activities | -1,892,000 | 5,672,000 |
Cash flows from investing activities: | ' | ' |
Additions to property, plant and equipment | -255,000 | -698,000 |
Change in restricted investments and bond collateral and reclamation deposits | 5,998,000 | -5,000 |
Cash payments related to Canadian acquisition | 0 | ' |
Cash acquired in related to Canadian acquisition | 0 | ' |
Net proceeds from sales of assets | 0 | 0 |
Proceeds from sale of investments | 0 | 0 |
Increase in loan and lease receivable | 0 | ' |
Receipts from loan and lease receivable | 0 | ' |
Receivable from customer for property and equipment purchases | 0 | 0 |
Other | 0 | ' |
Net cash used in investing activities | 5,743,000 | -703,000 |
Cash flows from financing activities: | ' | ' |
Change in book overdrafts | 0 | 0 |
Borrowings from long-term debt | 0 | ' |
Repayments of long-term debt | 0 | 0 |
Borrowings on revolving lines of credit | 0 | 0 |
Repayments on revolving lines of credit | 0 | 0 |
Debt issuance costs and other refinancing costs | 0 | 0 |
Dividends/distributions | -8,500,000 | -9,000,000 |
Exercise of stock options | 0 | ' |
Transactions with Parent/affiliates | 1,723,000 | -38,000 |
Net cash provided by (used in) financing activities | -6,777,000 | -9,038,000 |
Effect of foreign exchange rates on cash | 0 | ' |
Net increase (decrease) in cash and cash equivalents | -2,926,000 | -4,069,000 |
Cash and cash equivalents, beginning of period | 3,341,000 | 4,545,000 |
Cash and cash equivalents, end of period | 415,000 | 476,000 |
Guarantor Subsidiaries | ' | ' |
Cash flows from operating activities: | ' | ' |
Net income (loss) | -9,722,000 | 18,173,000 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity in income of subsidiaries | 0 | 0 |
Depreciation, depletion, and amortization | 35,373,000 | 24,554,000 |
Accretion of asset retirement obligation and receivable | 9,254,000 | 6,305,000 |
Non-cash tax benefits | 0 | ' |
Amortization of intangible assets and liabilities, net | 20,000 | 19,000 |
Share-based compensation | 497,000 | 2,181,000 |
Gain on sales of assets | -5,000 | -308,000 |
Amortization of deferred financing costs | 715,000 | 315,000 |
Loss on sales of investment securities | ' | -28,000 |
Loss on extinguishment of debt | 12,572,000 | 0 |
Loss (gain) on sales of investment securities | 3,000 | ' |
Derivative loss | 0 | ' |
Loss on foreign exchange | -1,092,000 | ' |
Income from equity affiliates | -799,000 | ' |
Distributions from equity affiliates | 730,000 | ' |
Changes in operating assets and liabilities: | ' | ' |
Receivables, net | -18,474,000 | 4,419,000 |
Inventories | 21,929,000 | -345,000 |
Excess of black lung benefit obligation over trust assets | 0 | 0 |
Deferred income tax | 3,854,000 | ' |
Accounts payable and accrued expenses | -3,164,000 | 904,000 |
Deferred revenue | -3,633,000 | -2,025,000 |
Income tax payable | 528,000 | -55,000 |
Accrual for workers' compensation | 0 | 0 |
Asset retirement obligations | -3,364,000 | -5,422,000 |
Accrual for postretirement medical benefits | 2,256,000 | 4,010,000 |
Pension and SERP obligations | -507,000 | 826,000 |
Other assets and liabilities | 4,113,000 | -1,489,000 |
Distributions received from subsidiaries | 0 | 0 |
Net cash provided by operating activities | 51,084,000 | 52,034,000 |
Cash flows from investing activities: | ' | ' |
Additions to property, plant and equipment | -17,122,000 | -12,189,000 |
Change in restricted investments and bond collateral and reclamation deposits | 11,673,000 | -7,902,000 |
Cash payments related to Canadian acquisition | -39,849,000 | ' |
Cash acquired in related to Canadian acquisition | 8,103,000 | ' |
Net proceeds from sales of assets | 213,000 | 577,000 |
Proceeds from sale of investments | 246,000 | 6,807,000 |
Increase in loan and lease receivable | -1,120,000 | ' |
Receipts from loan and lease receivable | 2,164,000 | ' |
Receivable from customer for property and equipment purchases | 0 | -307,000 |
Other | -82,000 | ' |
Net cash used in investing activities | -35,774,000 | -13,014,000 |
Cash flows from financing activities: | ' | ' |
Change in book overdrafts | 1,605,000 | 1,777,000 |
Borrowings from long-term debt | 0 | ' |
Repayments of long-term debt | -96,523,000 | -15,561,000 |
Borrowings on revolving lines of credit | 10,000,000 | 6,000,000 |
Repayments on revolving lines of credit | -10,000,000 | -6,000,000 |
Debt issuance costs and other refinancing costs | -11,646,000 | -156,000 |
Dividends/distributions | -68,300,000 | -27,600,000 |
Exercise of stock options | 0 | ' |
Transactions with Parent/affiliates | 157,581,000 | 8,699,000 |
Net cash provided by (used in) financing activities | -17,283,000 | -32,841,000 |
Effect of foreign exchange rates on cash | -1,038,000 | ' |
Net increase (decrease) in cash and cash equivalents | -3,011,000 | 6,179,000 |
Cash and cash equivalents, beginning of period | 27,451,000 | 10,237,000 |
Cash and cash equivalents, end of period | 24,440,000 | 16,416,000 |
Non-Guarantor Subsidiaries | ' | ' |
Cash flows from operating activities: | ' | ' |
Net income (loss) | 296,000 | 1,045,000 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity in income of subsidiaries | 0 | 0 |
Depreciation, depletion, and amortization | 0 | 0 |
Accretion of asset retirement obligation and receivable | 0 | 1,000 |
Non-cash tax benefits | 0 | ' |
Amortization of intangible assets and liabilities, net | 0 | -5,000 |
Share-based compensation | 0 | 0 |
Gain on sales of assets | 0 | 0 |
Amortization of deferred financing costs | 0 | 0 |
Loss on sales of investment securities | ' | 0 |
Loss on extinguishment of debt | 1,000 | 0 |
Loss (gain) on sales of investment securities | 0 | ' |
Derivative loss | 0 | ' |
Loss on foreign exchange | 0 | ' |
Income from equity affiliates | 0 | ' |
Distributions from equity affiliates | 0 | ' |
Changes in operating assets and liabilities: | ' | ' |
Receivables, net | 4,733,000 | -239,000 |
Inventories | -1,000 | 0 |
Excess of black lung benefit obligation over trust assets | 0 | -1,000 |
Deferred income tax | 0 | ' |
Accounts payable and accrued expenses | -4,526,000 | -1,146,000 |
Deferred revenue | 0 | 1,000 |
Income tax payable | 0 | -1,000 |
Accrual for workers' compensation | 0 | 0 |
Asset retirement obligations | 2,000 | -2,000 |
Accrual for postretirement medical benefits | 38,000 | 124,000 |
Pension and SERP obligations | 7,000 | -13,000 |
Other assets and liabilities | -1,193,000 | -374,000 |
Distributions received from subsidiaries | 0 | 0 |
Net cash provided by operating activities | -643,000 | -610,000 |
Cash flows from investing activities: | ' | ' |
Additions to property, plant and equipment | 0 | -4,000 |
Change in restricted investments and bond collateral and reclamation deposits | 0 | 0 |
Cash payments related to Canadian acquisition | 0 | ' |
Cash acquired in related to Canadian acquisition | 0 | ' |
Net proceeds from sales of assets | 0 | 0 |
Proceeds from sale of investments | 0 | 0 |
Increase in loan and lease receivable | 0 | ' |
Receipts from loan and lease receivable | 0 | ' |
Receivable from customer for property and equipment purchases | 0 | -1,000 |
Other | 0 | ' |
Net cash used in investing activities | 0 | -5,000 |
Cash flows from financing activities: | ' | ' |
Change in book overdrafts | 0 | 0 |
Borrowings from long-term debt | 0 | ' |
Repayments of long-term debt | 0 | -9,000 |
Borrowings on revolving lines of credit | 0 | 0 |
Repayments on revolving lines of credit | 0 | 0 |
Debt issuance costs and other refinancing costs | 0 | 0 |
Dividends/distributions | 0 | 0 |
Exercise of stock options | 0 | ' |
Transactions with Parent/affiliates | -2,108,000 | 2,349,000 |
Net cash provided by (used in) financing activities | -2,108,000 | 2,340,000 |
Effect of foreign exchange rates on cash | 0 | ' |
Net increase (decrease) in cash and cash equivalents | -2,751,000 | 1,725,000 |
Cash and cash equivalents, beginning of period | 4,992,000 | 1,992,000 |
Cash and cash equivalents, end of period | 2,241,000 | 3,717,000 |
Consolidating Adjustments | ' | ' |
Cash flows from operating activities: | ' | ' |
Net income (loss) | 17,268,000 | -23,047,000 |
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ' | ' |
Equity in income of subsidiaries | -16,148,000 | 27,450,000 |
Depreciation, depletion, and amortization | 0 | 0 |
Accretion of asset retirement obligation and receivable | 0 | 0 |
Non-cash tax benefits | 0 | ' |
Amortization of intangible assets and liabilities, net | 0 | 0 |
Share-based compensation | 0 | 0 |
Gain on sales of assets | 0 | 0 |
Amortization of deferred financing costs | 0 | 0 |
Loss on sales of investment securities | ' | 0 |
Loss on extinguishment of debt | 0 | 0 |
Loss (gain) on sales of investment securities | 0 | ' |
Derivative loss | 0 | ' |
Loss on foreign exchange | 0 | ' |
Income from equity affiliates | 0 | ' |
Distributions from equity affiliates | 0 | ' |
Changes in operating assets and liabilities: | ' | ' |
Receivables, net | 1,534,000 | 1,729,000 |
Inventories | 0 | 0 |
Excess of black lung benefit obligation over trust assets | 0 | 0 |
Deferred income tax | 0 | ' |
Accounts payable and accrued expenses | -19,000 | -201,000 |
Deferred revenue | 0 | 0 |
Income tax payable | 0 | 0 |
Accrual for workers' compensation | 0 | 0 |
Asset retirement obligations | 0 | 0 |
Accrual for postretirement medical benefits | 0 | 0 |
Pension and SERP obligations | 0 | 0 |
Other assets and liabilities | 6,587,000 | 0 |
Distributions received from subsidiaries | -76,800,000 | -36,600,000 |
Net cash provided by operating activities | -67,578,000 | -30,669,000 |
Cash flows from investing activities: | ' | ' |
Additions to property, plant and equipment | 0 | -1,000 |
Change in restricted investments and bond collateral and reclamation deposits | 0 | 0 |
Cash payments related to Canadian acquisition | 0 | ' |
Cash acquired in related to Canadian acquisition | 0 | ' |
Net proceeds from sales of assets | 0 | 0 |
Proceeds from sale of investments | 0 | 0 |
Increase in loan and lease receivable | 0 | ' |
Receipts from loan and lease receivable | 0 | ' |
Receivable from customer for property and equipment purchases | 0 | 0 |
Other | 0 | ' |
Net cash used in investing activities | 0 | -1,000 |
Cash flows from financing activities: | ' | ' |
Change in book overdrafts | 0 | 0 |
Borrowings from long-term debt | 0 | ' |
Repayments of long-term debt | 0 | 0 |
Borrowings on revolving lines of credit | 0 | 0 |
Repayments on revolving lines of credit | 0 | 0 |
Debt issuance costs and other refinancing costs | 0 | 0 |
Dividends/distributions | 76,800,000 | 36,600,000 |
Exercise of stock options | 0 | ' |
Transactions with Parent/affiliates | -9,222,000 | -5,930,000 |
Net cash provided by (used in) financing activities | 67,578,000 | 30,670,000 |
Effect of foreign exchange rates on cash | 0 | ' |
Net increase (decrease) in cash and cash equivalents | 0 | 0 |
Cash and cash equivalents, beginning of period | 0 | 0 |
Cash and cash equivalents, end of period | $0 | $0 |